Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TXN | P10599 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377059 | 1.00 | TAAR1 (0.47) | TAAR1AAK1MMP1MMP3MMP7 | |
| SCHEMBL7407227 | 1.00 | TAAR1 (0.47) | TAAR1AAK1MMP1MMP3MMP7 | |
| SCHEMBL1306359 | 0.82 | — | — | |
| SCHEMBL7416391 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL18689306 | 0.80 | TXN (0.40) | ADRA2AADRA2BADRA2CALDH1A1SMN1; SMN2 | |
| SCHEMBL7738284 | 0.79 | MMP1 (0.42) | TAAR1MMP1MMP3MMP7ADRA2A | |
| SCHEMBL2576594 | 0.79 | — | — | |
| SCHEMBL1905054 | 0.79 | — | — | |
| SCHEMBL7421789 | 0.78 | FPR2 (0.41) | ADRA2AADRA2BADRA2CALDH1A1SMN1; SMN2 | |
| SCHEMBL2929069 | 0.78 | FPR2 (0.41) | ADRA2AADRA2BADRA2CALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| CN-1233237-A | Heteroaryl succinamides and their use as metalloproteinase inhibitors | AGOURON PHARMA (US) | 1999-10-27 | — | — | CN | disclosed |
| EP-0828732-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE | Chiroscience Limited (GB) | 1998-03-18 | — | — | EP | disclosed |
| US-5698706-A | BLOCKING TUMOR NECROSIS FACTOR | CHIROSCIENCE LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| WO-1996035687-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | MMP9, MMP2, MMP3 | TAAR1 4474/4885AAK1 4671/4885MMP1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.